Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
275 stopped studies mapped to Malignant Urinary Tract Neoplasm and descendants · 93% state a reason
Over the 275 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT06422312 | A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. | N/A | withdrawn | May 20, 2024 | Guangzhou Red Pine Medical Instrument Co., Ltd. | A change in marketing strategy resulted in a decision to not complete the trial. | Sponsor / business decision |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT02053662 | Biomarker Identification for Bladder Cancer Patients | — | terminated | Feb 4, 2014 | Ohio State University Comprehensive Cancer Center | No publishable data was acquired from the study and the primary researcher left over 5 years ago. | Other (stated, no rule matched) |
| NCT04322643 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Phase 2 | terminated | Mar 26, 2020 | Case Comprehensive Cancer Center | PI preference | Other (stated, no rule matched) |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jun 23, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02538809 | Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals | — | terminated | Sep 2, 2015 | Swiss Paraplegic Research, Nottwil | insufficient recruitment | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03286699 | Lifestyle Change for Better Health(LCBH) | N/A | terminated | Sep 18, 2017 | University of Pittsburgh | Due to challenges with recruitment, we were unable to complete recruitment as planned during the… | Enrollment / accrual |
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial… | Phase 2 | terminated | Sep 5, 2017 | Arjun Balar, MD | Funder decision | Other (stated, no rule matched) |
| NCT04228042 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | Phase 1 / Phase 2 | terminated | Jan 14, 2020 | M.D. Anderson Cancer Center | Drug manufacturer made the business decision to cease all infigratinib oncology research in the US… | Drug supply |
| NCT04871529 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and… | Phase 2 | terminated | May 4, 2021 | SWOG Cancer Research Network | inability to accrue sufficient patients | Enrollment / accrual |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Phase 2 | withdrawn | Aug 21, 2019 | MedPacto, Inc. | Changing trial strategy | Sponsor / business decision |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects…(ABLE-42) | Phase 4 | withdrawn | Apr 30, 2024 | Ferring Pharmaceuticals | Ferring decided to prioritize collection of ADSTILADRIN re-induction data in patients with HR… | Other (stated, no rule matched) |
| NCT03486197 | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced… | Phase 2 | terminated | Apr 3, 2018 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without… | Phase 1 / Phase 2 | terminated | Dec 31, 2020 | Istari Oncology, Inc. | business decision | Sponsor / business decision |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04583553 | Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients…(VS-UrineID) | — | withdrawn | Oct 12, 2020 | University of Kansas Medical Center | Site did not proceed with study. | Other (stated, no rule matched) |
| NCT05846165 | InveStigAting Bladder fiELd-cycLing imAging(ISABELLA) | N/A | withdrawn | May 6, 2023 | University of Aberdeen | No participants identified. Funding ended | Funding |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has… | Phase 2 | withdrawn | May 22, 2024 | EMD Serono Research & Development Institute, Inc. | Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No… | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy… | Phase 2 | terminated | Jan 27, 2011 | Merck Sharp & Dohme LLC | Persistent low enrollment made study continuation no longer feasible | Enrollment / accrual |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline… | Phase 2 | withdrawn | Oct 10, 2022 | AdventHealth | PI Decision based on no enrollment | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of…(Immune PDX) | — | terminated | Apr 28, 2017 | Duke University | Poor accrual | Enrollment / accrual |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | Phase 1 | withdrawn | Feb 21, 2023 | Insel Gruppe AG, University Hospital Bern | IMP security Issues reported by Sponsor | Other (stated, no rule matched) |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder…(ATLAS) | Phase 3 | terminated | Dec 30, 2020 | UroGen Pharma Ltd. | Alternate approach pursued | Other (stated, no rule matched) |
| NCT05643690 | Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay | — | suspended | Dec 9, 2022 | AnchorDx Medical Co. Ltd. US | Protocol amendment. | Other (stated, no rule matched) |
| NCT03915405 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Phase 1 | terminated | Apr 16, 2019 | Kyowa Kirin, Inc. | Termination was based on the business decision | Sponsor / business decision |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People… | — | terminated | Jan 26, 2023 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a… | Phase 3 | withdrawn | Mar 8, 2024 | Second Xiangya Hospital of Central South University | The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this,… | Enrollment / accrual |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT04806334 | Radiogenomics of Muscle Invasive Bladder Cancer | N/A | terminated | Mar 19, 2021 | Cedars-Sinai Medical Center | Slow accrual | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in… | Phase 1 | withdrawn | Jun 8, 2023 | Weill Medical College of Cornell University | Insufficient funding | Funding |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | N/A | withdrawn | Apr 10, 2019 | University Health Network, Toronto | This study is being closed. The protocol may be reviewed and consolidated under a new study… | Other (stated, no rule matched) |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial…(PROOF302) | Phase 3 | terminated | Dec 13, 2019 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development.… | Safety / toxicity |
| NCT05335707 | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With… | — | withdrawn | Apr 19, 2022 | University of Kansas Medical Center | Study funds ended on 7/31/2023 | Funding |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for…(CANUCK-01) | Phase 2 | withdrawn | Aug 30, 2023 | CHU de Quebec-Universite Laval | Results of EV302 study do not make it feasible to complete a study in second line avelumab… | Other (stated, no rule matched) |
| NCT04779489 | Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer(CIRTiN-BC) | N/A | terminated | Mar 3, 2021 | University of Texas Southwestern Medical Center | Study was closed to low accrual. | Enrollment / accrual |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | N/A | terminated | Apr 10, 2020 | University of Oklahoma | Study funding was withdrawn. | Funding |
| NCT02887248 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or… | Phase 2 | terminated | Sep 2, 2016 | SCRI Development Innovations, LLC | Enrollment issues | Enrollment / accrual |
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced… | Phase 2 | terminated | Oct 6, 2010 | Matthew Galsky | Lack of Accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 9, 2025source: clinicaltrials